Following Janssen flu deal, Leyden Labs gets $140M led by Casdin Capital and GV

Leyden Labs is developing nasal spray medicines to prevent respiratory viral infections. The company’s Series B round of funding follows a licensing deal that gives the biotech rights to a Janssen antibody designed to address the two types of influenza that cause seasonal flu.

Related Keywords

Boston ,Massachusetts ,United States ,Amsterdam ,Noord Holland ,Netherlands ,Johnson Covid ,Centers For Disease ,Leyden Lab ,Softbank Vision Fund ,Leyden Labs ,Disease Control ,Medcity News ,Bluebird Ventures ,F Prime Capital ,Weight Loss ,Obesity ,Verweight ,Diabetes ,Medical Devices ,Startups ,Healthcare Innovation ,San Francisco ,Life Sciences ,Accelerator ,Rock Health ,Startup Advice ,Startup Funding ,Patient Monitoring System ,Otion Sensors ,Dc ,Healthcare It ,Washington ,Foodborne Pathogens ,Iagnostics Company ,Iagnostic Platforms ,Minimally Invasive Surgery ,Aser Surgery ,Cambridge ,Dealflow ,Hospitals ,Wellpoint ,Ealthways ,Ealth And Wellness ,Mployee Wellness Programs ,Investing ,Wellness ,Medtronic ,Hanghai Innovation Center ,China ,R D ,Mdt ,Minneapolis ,Minnesota ,Publics ,Twin Cities ,Ulcerative Colitis ,Abbott Labs ,Humira ,Doctors ,Pharmaceuticals ,Skin Disorders ,D Anderson Cancer Center ,Cancer ,Texas ,Renal Denervation ,St Jude Medical ,Stj ,Emr ,Hr ,Electronic Health Records ,Electronic Medical Records ,Certified Emr ,Ehr ,Advanced Cellular Technology ,Amyotrophic Lateral Sclerosis ,Embryonic Stem Cells ,Geron Corporation ,Lou Gehrigs Disease ,Macular Degeneration ,Regenerative Medicine ,Spinal Cord Damage ,Value Based Healthcare System ,Obamacare ,Ee For Service Model ,California ,Cleveland ,Health Insurance ,Insurance ,Ohio ,Pennsylvania ,Politics ,Cancer Treatment Options Library ,Aetna ,Pet ,Aet ,Health It ,Phi ,Philadelphia ,Antiviral ,Clinical Trials ,Coronavirus ,Covid 19 ,Deals ,Influenza ,Koenraad Wiedhaup , ,